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Background and methods: Achromobacter species leads to chronic infection in an increasing number of CF patients. We report 2 cases of
Achromobacter ruhlandii cross-infection between patients after well-described indirect contact.
Results: Both cases were young, stable, CF patients without chronic infections and with normal FEV1, but experienced clinical deterioration after
visits to the home of a CF patient with A. ruhlandii infection and after sharing facilities with an A. ruhlandii infected CF patient on a skiing
vacation, respectively. Both cases became positive for A. ruhlandii in airway secretions and were colonized with A. ruhlandii in their sinuses.
Aggressive, long-term antibiotic treatment led to clinical stability. One of the cases developed chronic A. ruhlandii infection.
Conclusion: A. species can cause cross-infection even after a short period of indirect contact between infected and non-infected CF patients.
Patients should be followed closely for several months before the possibility of cross-infection is ruled out.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cross-infection; Achromobacter xylosoxidans; Pulmonary infection1. Introduction
In cystic fibrosis (CF) patients, chronic, pulmonary infection
caused by Achromobacter species is an increasing problem.
Antibiotic resistance is common in A. species infection and
develops early, making antibiotic treatment difficult. Although the
prevalence of chronic A. species infection is low in most CF
centers, chronic A. species infection may lead to rapid clinical
deterioration in affected patients [2,3].
In the case of other Gram-negative infections in CF patients,
cross-infection has been shown to take place with Pseudomonas
aeruginosa [4–8] and Burkholderia cepacia complex (BCC)☆ Data have been presented at the 35th European Cystic Fibrosis Conference
in Dublin, June 2012, as abstract number 353 [1].
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http://dx.doi.org/10.1016/j.jcf.2013.05.004,lished[9–13] and recommendations are to avoid close contact between
chronically infected patients and patients without chronic, Gram-
negative infections [14–16].
Transmission of A. species between CF patients has previously
been reported [17]. Studies have shown transmission between
closely related CF patients, i.e. siblings [18], or patients known to
have had close, prolonged contact [3,19–23].
We present 2 cases of cross-infection between CF patients with
no direct, but well-described indirect contact.2. Methods
2.1. Study design
Clinical data used in this study were collected prospectively
and stored in the Copenhagen CF Centre database from time of
diagnosis and onwards.by Elsevier B.V. All rights reserved.
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this work, data were gathered retrospectively from the database.2.2. Patients
All CF patients are seen on a regular, monthly basis. At all
visits, the clinical status of the patients is assessed by weight,
height and lung function parameters, forced vital capacity (FVC)
and forced expiratory volume in 1s (FEV1) (Masterscreen
Pneumo, Jaeger) are obtained according to the American
Thoracic Society guidelines, using reference values from Wang
[24] and Hankinson et al. [25]. Lower respiratory tract
secretions for microbiological investigation are obtained by
coughing or by endo-laryngeal suctioning. Specific, precipi-
tating antibodies are obtained at least once every year, in
patients with a chronic lung infection every third month.
Chronic infection is defined as more than 50% of positive
sputum samples and/or elevated levels of specific, precipitat-
ing antibodies [26]. Intermittent colonization is defined as
isolation of a CF related Gram-negative rod in less than 50% of
the investigated sputum samples in the present year (P.
aeruginosa, A. species, Pandoraeae apista or a BCC species)
in a patient with no increase in specific antibodies. The
diagnosis of CF is based on abnormal sweat electrolytes,
characteristic clinical features and CFTR genotype.2.3. Segregation policy
In the clinic, patients with CF-related chronic Gram-negative,
pulmonary infections are isolated from patients without chronic
infections, and patients are encouraged to avoid social interaction
with other CF patients with chronic Gram-negative, pulmonary
infections.
All horizontal surfaces are cleaned after an infected patient has
been in a room, and the hygienic procedures are in accordance
with the recommendations of the department of infection control
in the hospital.2.4. Pulsed field gel electrophoresis (PFGE)
Strains isolated from individual patients are stored on a
yearly basis, and PFGE [27,28], using Spe I as restriction
enzyme, is performed regularly to discover possible cases of
cross-infection.2.5. Multilocus sequence analysis
Isolates from the 2 cases and from the 2 chronically infected CF
patients were investigated using multilocus sequence analysis [17]
and compared to a reference strain of Achromobacter ruhlandii,
the Danish epidemic strain that has infected multiple patients at
Danish CF centers in Aarhus and Copenhagen [3,17,23], as
previously described.3. Results
3.1. Case 1: A girl born in April 1999
Diagnosis was made shortly after birth due to meconium
ileus. Her CFTR genotype is ΔF508 homozygous and she has
been followed with monthly controls in the outpatient clinic
since diagnosis. Daily treatment included pancreatic enzyme
replacement since birth, lung physiotherapy and from the age of
21 months, also daily Pulmozyme® inhalation.
Monthly endolaryngeal suctioning revealed intermittent colo-
nization with Streptococcus pneumoniae, Moraxella catarrhalis,
Haemophilus influenzae and occasionally Staphylococcus aureus.
All infections were treated with 2 week courses of oral antibiotics.
Case 1 had had 2 isolates of P. aeruginosa. First ever isolate of
P. aeruginosa was cultured in April 2006 and treated with
4 weeks of inhaled colomycin and oral ciprofloxacin. Second
isolate of P. aeruginosa was cultured in March 2007 and was
treated with 3 months of inhaled colomycin and oral ciproflox-
acin. This time, the patient had an asthmatic reaction to colomycin
and received bronchodilator-treatment.
Measurement of lung function was performed since the age
of 5.5 years and was stable with FEV1 above 100 % predicted
(Fig. 1).
The girl lives in a small village on an isolated island. In
2006, another CF patient moved to the village with her family,
including 2 twin sisters (non-CF) of the same age as Case 1.
The 3 girls became friends and Case 1 came in the home of the
2 twin sisters and their 9 years older sister with CF and chronic
A. ruhlandii infection, the Danish epidemic strain. The parents
took great care never letting the 2 CF patients stay in a room
simultaneously.
After completion of 3 months of anti-P. aeruginosa treatment
in June 2007, Case 1 experienced weight-loss and a dramatic
decline in lung function and showed no effect of bronchodilator-
treatment.
Within a few weeks, sputum samples became positive for
multi-resistant A. species, only sensitive to sulfometoxazole.
PFGE showed that the A. ruhlandii strains from Case 1 and from
the older CF patient were identical, indicating patient-to-patient
transmission, and multilucos sequence analysis confirmed that
Case 1 harbored the Danish epidemic strain (Fig. 3).
In April 2008, functional endoscopic sinus surgery (FESS)
was performed and A. ruhlandii was cultured from the sinuses.
Inhaled ceftazidime and oral sulfometoxazole and trimetoprim
were started immediately after culture of first isolate of
A. ruhlandii. Inhaled ceftazidime has been given continuously
since then and supplemented with courses of oral antibiotics and/
or iv. antibiotics. In August 2008, inhaled antibiotics were
changed to colomycin, but again the patient had an asthmatic
reaction with a dramatic decline in lung function. Lung function
immediately stabilized when treatment was switched back to
ceftazidime.
The patient is clinically stabilized, but sputum cultures remain
positive for A. ruhlandii and specific, precipitating anti-A. species
antibodies have increased to a steady level around 7–10, and the
































Fig. 1. Case 1, lung function, microbiology and treatment from 2006 until January 2013. FEV1 and FVC are shown as % of predicted. Top bars show period of possible
transmission (open) and period of antibiotic treatment (gray, shown as ceftazidime inhalation). Lightning shows first isolation of A. ruhlandii (Danish Epidemic Strain).
Five-pointed star shows FESS. Open circles show intermittent colonization with P. aeruginosa. At the bottom, level of specific, precipitating anti-A. species antibodies is shown
at different time-points.
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Diagnosis was made shortly after birth due to meconium
ileus. Sweat test was positive with sodium-concentration above
80 mmol/l. CF genotype was difficult to identify, but the boy,
who is of Pakistani origin, is heterozygous with mutations del
ex 11,12 and del ex 12,13,14A, respectively. These mutations
have not been classified, but the phenotype of this patient is
classical CF. During the first 2 years of life, the boy had
compliance and nutritional problems. Following replacement in
an institution his clinical condition improved. Daily treatment
included pancreatic enzyme replacement since birth, lung
physiotherapy and from the age of 4.5 years, also daily
Pulmozyme® inhalation.
Monthly cultures obtained by endo-laryngeal suctioning
revealed intermittent colonization with H. influenzae, S. aureus,
and M. catarrhalis. All infections were treated with 2 week
courses of oral antibiotics.
Case 2 had only had P. aeruginosa once in May
2007, treated with 3 months of inhaled colomycin and oral
ciprofloxacin.
Measurement of lung function was performed since the age
of 6.5 years and was stable with FEV1 around 80% of predicted
(Fig. 2).
In January 2011, the boy went on a one week skiing holiday
with the institution in which he lives. Another CF patient,
22 years old, chronically infected with the Danish epidemic
strain of A. ruhlandii, also attended the ski-camp. The 2 CF
patients did not have close contact and slept in separate rooms,
but shared dining and living facilities.Over the next 6 months, Case 2 experienced fatigue and an
ongoing decline in lung function, but no increase in cough or
sputum production. Sputum samples grew H. influenzae
once, but were otherwise negative. Chest X-ray revealed
increased air-trapping. Blood samples showed numbers of
specific, precipitating anti-A. species antibodies increasing from
0 to 6.
Broncho-alveolar lavage (BAL) was performed in July 2011 in
order to hopefully explain the symptoms. The BAL-fluid showed
multi-resistant A. species, only partially sensitive to piperacillin
with tazobactam, ciprofloxacin, imipenem, tigecycline and
chloramphenicol.
PFGE showed that strains from Case 2 and the adult CF
patient were identical, indicating that transmission and multilucos
sequence analysis confirmed that Case 2 harbored the Danish
epidemic strain (Fig. 3).
In October 2011, FESS was performed and A. ruhlandii was
cultured in secretions from the sinuses.
Immediately after culture of A. ruhlandii in BAL-fluid,
antibiotic treatment was initiated with a course of iv. piperacillin
with tazobactam and oral ciprofloxacin. After finishing this
course, the patient has been inhaling ceftazidime continuously
and is having 2 weeks iv.-courses every 3 months.
Lung function has stabilized on antibiotic treatment, and the
patient has not yet had growth of A. ruhlandii in spontaneously
expectorated sputum, but levels of specific, precipitating anti-A.
ruhlandii antibodies remained increased in 2011, but have been
decreasing in 2012 to 1 during constant ceftazidime-inhalation.


























Fig. 2. Case 2, lung function, microbiology and treatment from 2009 until January 2013. FEV1 and FVC are shown as % of predicted. Top bars show period of
possible transmission and period of antibiotic treatment (shown as ceftazidime inhalation). Lightning shows first isolation of A. ruhlandii (Danish Epidemic Strain).
Five-pointed star shows sinus-surgery. At the bottom, level of specific, precipitating anti-A. species antibodies is shown at different time-points.
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The incidence of chronic, pulmonary A. species infection in
CF patients has increased over the past few years. Several cases
of cross-infections have been described, but until now, cross-
infection has only been known to happen after close, prolonged
contact between CF patients with chronic A. species infection and
patients without infection.
In the present work, two clinically stable CF patients with
normal lung function, without chronic, Gram-negative, pulmo-
nary infections acquired A. ruhlandii after indirect contact to
other CF patients chronically infected with the Danish epidemic
strain of A. ruhlandii. Interestingly, both patients experienced
clinical deterioration for a few months before A. ruhlandii was
isolated, suggesting that clinical symptoms due to A. ruhlandii
are possible even in the very early stages of a chronic infection.
No other cause of the clinical deterioration was found in either
patient, and in Case 2, A. ruhlandii was not found until a BAL
was performed. To our knowledge, no other studies have
presented clinical symptoms so shortly after acquiring the
infection.
The finding of multi-resistant strains was very suspicious
for transmission. Although A. species develops multi-
resistance against antibiotics very fast, initial isolates are
often antibiotic sensitive, leaving a few different treatment
options [29,30]. However, no direct contact between the cases
and the chronically infected CF patients had occurred to our
knowledge. These patients were not of a similar age, and cross
infection was not expected initially, since the segregation
policy of the Copenhagen CF center does not allow patients
with chronic A. species infection to be in contact with
non-infected patients. Only after the PFGE results, showingidentical strains in the cases and respective chronically infected
CF patients, were the circumstances regarding possible
transmission explored. The mechanism of transmission in our
cases is probably due to the presence of A. ruhlandii on
horizontal surfaces, door handles or in aerosols, since the
patients did not have direct contact with each other. It has been
shown that CF pathogens can be cultured from the surround-
ings of CF patients, originating from cough-generated aerosols
[31]. Peltroche-Llacsahuanga et al. describe 2 CF brothers in
whom the younger brother only developed chronic A. species
infection 3 years after his older brother [18]. The brothers lived
together, and transmission was expected to occur earlier.
A group of Danish teenagers have shared the same
A. species strain for several years (the Danish epidemic strain)
[3,23]. This strain was recently identified as A. ruhlandii [17].
The affected patients are known to have had close, social
contact over several years outside the hospital, and cross-
infection occurred before the segregation policy for A. species
was introduced in the Danish CF centers. Why this specific
strain became epidemic has not yet been clarified. Other strains
of A. species have been shown to lead to cross-infection [17],
but it is noteworthy that it was the Danish epidemic strain
leading to cross-infection after indirect contact for a shorter
time period.
In a study by van Daele et al., transmission of not only
A. species [20], but also P. aeruginosa [32] took place at a
Belgian rehabilitation center. In the center, CF patients lived in
separate rooms, but shared dining and living facilities. The
patients stayed at the center for a median of 63 days [32], and not
everyone was colonized with the transmissible strains after the
stay. These results add to the evidence of transmission needing
time to occur.
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point harbored A. species [22]. Five patients were chronically
infected, among these 2 sets of siblings sharing identical strains.
A total of 22 of the 39 included patients at some point shared the
same A. species clone. Authors suggest that transmission possibly
occurred during visits to the hospital. This is the first study
describing A. species cross infection in a larger group of CF
patients.
De Baets et al. [2] found that patients developing chronic
A. species infection had worse lung function and radiological
evidence of more pronounced lung damage on chest X-rays and
high resolution CT scans compared to CF patients not developing
chronic A. species infection and suggest that chronic A. species
infection mainly develop in CF patients with increased pulmonary
damage [33]. In several studies, chronic P. aeruginosa infection
was established prior to the development of chronic A. species
infection [19,33–38], and may be the cause of significant
pulmonary damage increasing the risk of development of other
chronic, pulmonary infections. In 2 studies published by our own
group, the majority of CF patients with chronic A. species
infection did not harbor any co-infections, however [3,39].
In our study, A. ruhlandii was not found in the Case 2 until
several months after contact to infected patient. This shows the
importance of frequent, clinical and microbiological follow-up
in CF patients in order to discover new infections, but also
before the possibility of cross infection can be ruled out.
In both cases, intensive endoscopic sinus surgery revealed
A. ruhlandii in sinus secretions and it is possible that sinus
colonization with A. species preceded the development of
pulmonary infection.
Focus on sinuses as a bacterial reservoir (united airways) has
increased in CF patients [40], and newer studies support the
theory of chronic, pulmonary P. aeruginosa infections beginning
as rhino-sinusitis, dripping bacteria to the lower airways, thereby
leading to pulmonary infection [41–43]. In one of our cases,
A. ruhlandii was found exclusively in sinus secretions and in
BAL-fluid but not in sputum, although the patient experienced
clinical deterioration and the level of precipitating antibodies
increased. CF patients with unexplained lung function decline and
clinical deterioration should undergo thorough investigation –
especially if sputum samples are negative – in order to diagnose
possible lower airway or sinus infection. These investigations
should include sinus examination, and infection can only be ruled
out if sinus samples as well as BAL-fluid cultures are negative.
In a new study by Wang et al. (manuscript submitted), use of
inhaled antibiotics was found to be valuable in clearing
A. species infection in CF patients with first ever isolate. The
use of continuous inhaled antibiotics in the 2 cases described
here is possibly an important reason for the clinical stability of
the cases, even after fulfilling the criteria for development of
chronic infection.Fig. 3. Multilocus sequence analysis showing the 4 isolates from the cases and
the chronically infected patients. These 4 isolates cluster with the Danish
epidemic strain of A. ruhlandii, strain A83.
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A. species is capable of causing cross infection even if direct
contact between patients is avoided. If known indirect contact has
happened, the patient should be followed closely for several
months before the possibility of cross-infection is ruled out.
Symptoms of pulmonary exacerbation do not necessarily present
and the occurrence of A. species in sputum cultures can be
delayed for weeks after cross-infection.
Like P. aeruginosa, A. species can colonize the sinuses and
when evaluating a CF patient experiencing clinical deterioration,
examination of the sinuses should be part of the assessment, since
chronic rhinosinusitis might lead to chronic, lower airway
infection in these patients.
A. species is capable of causing cross-infection even after
short, indirect contact between infected and non-infected CF
patients.References
[1] Hansen CR, Pressler T, Johansen HK, Skov M. Achromobacter
xylosoxidans in cystic fibrosis: indirect patient-to-patient contact can
lead to cross-infection.J Cyst Fibros 2012;11(Supplement 1):S147 [Ref
Type: Abstract].
[2] Romano L, Bellodi S, Lugani F, Manno G. To the editor: alcaligenes as a
pathogen in airways chronic infection in cystic fibrosis. Pediatr Pulmonol
May 2003;35(5):412–3.
[3] Rønne Hansen C, Pressler T, Høiby N, Gormsen M. Chronic infection
with Achromobacter xylosoxidans in cystic fibrosis patients: a retrospective
case control study. J Cyst Fibros Dec 2006;5(4):245–51.
[4] Denton M, Kerr K, Mooney L, Keer V, Rajgopal A, Brownlee K, et al.
Transmission of colistin-resistantPseudomonas aeruginosa between patients
attending a pediatric cystic fibrosis center. Pediatr Pulmonol Oct 2002;34(4):
257–61.
[5] Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas
aeruginosa infection in Danish cystic fibrosis patients (1974–1995). Pediatr
Pulmonol Sep 1999;28(3):159–66.
[6] Høiby N, Pedersen SS. Estimated risk of cross-infection with Pseudomonas
aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand May
1989;78(3):395–404.
[7] Ojeniyi B, Frederiksen B, Høiby N. Pseudomonas aeruginosa cross-
infection among patients with cystic fibrosis during a winter camp. Pediatr
Pulmonol Mar 2000;29(3):177–81.
[8] Pedersen SS, Koch C, Høiby N, Rosendal K. An epidemic spread of
multiresistantPseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob
Chemother Apr 1986;17(4):505–16.
[9] LiPuma JJ, Marks-Austin KA, Holsclaw Jr DS, Winnie GB, Gilligan
PH, Stull TL. Inapparent transmission of Pseudomonas (Burkholderia)
cepacia among patients with cystic fibrosis. Pediatr Infect Dis J Aug
1994;13(8):716–9.
[10] Mahenthiralingam E, Baldwin A, Vandamme P. Burkholderia cepacia
complex infection in patients with cystic fibrosis. J Med Microbiol Jul
2002;51(7):533–8.
[11] Muhdi K, Edenborough FP, Gumery L, O'Hickey S, Smith EG, Smith
DL, et al. Outcome for patients colonised with Burkholderia cepacia in a
Birmingham adult cystic fibrosis clinic and the end of an epidemic.
Thorax Apr 1996;51(4):374–7.
[12] Whiteford ML, Wilkinson JD, McColl JH, Conlon FM, Michie JR, Evans
TJ, et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in
children with cystic fibrosis following a hospital outbreak. Thorax Nov
1995;50(11):1194–8.
[13] Burns JL. Burkholderia cepacia—a transmissible cystic fibrosis pathogen.
J Pediatr Nov 2001;139(5):618–9.[14] Döring G, Høiby N. Early intervention and prevention of lung disease in
cystic fibrosis: a European consensus. J Cyst Fibros Jun 2004;3(2):67–91.
[15] France MW, Dodd ME, Govan JR, Doherty CJ, Webb AK, Jones AM.
The changing epidemiology of Burkholderia species infection at an adult
cystic fibrosis centre. J Cyst Fibros Sep 2008;7(5):368–72.
[16] Saiman L, Siegel J. Infection control recommendations for patients with
cystic fibrosis: microbiology, important pathogens, and infection control
practices to prevent patient-to-patient transmission. Infect Control Hosp
Epidemiol May 2003;24(5 Suppl.):S6–S52.
[17] Ridderberg W, Wang M, Norskov-Lauritsen N. Multilocus sequence
analysis of isolates of Achromobacter from patients with cystic fibrosis
reveals infecting species other than Achromobacter xylosoxidans. J Clin
Microbiol Aug 2012;50(8):2688–94.
[18] Peltroche-Llacsahuanga H, Haase G, Kentrup H. Persistent airway
colonization with Alcaligenes xylosoxidans in two brothers with cystic
fibrosis. Eur J Clin Microbiol Infect Dis Feb 1998;17(2):132–4.
[19] Kanellopoulou M, Pournaras S, Iglezos H, Skarmoutsou N, Papagrangas
E, Maniatis AN. Persistent colonization of nine cystic fibrosis patients with
an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol
Infect Dis Apr 2004;23(4):336–9.
[20] van Daele S, Verhelst R, Claeys G, Verschraegen G, Franckx H, van
Simaey L, et al. Shared genotypes of Achromobacter xylosoxidans strains
isolated from patients at a cystic fibrosis rehabilitation center. J Clin
Microbiol Jun 2005;43(6):2998–3002.
[21] Raso T, Bianco O, Grosso B, Zucca M, Savoia D. Achromobacter
xylosoxidans respiratory tract infections in cystic fibrosis patients. APMIS
Sep 2008;116(9):837–41.
[22] Pereira RH, Carvalho-Assef AP, Albano RM, Folescu TW, Jones MC,
Leao RS, et al. Achromobacter xylosoxidans: characterization of strains in
Brazilian cystic fibrosis patients. J Clin Microbiol Oct 2011;49(10):
3649–51.
[23] Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, et al. Marked
increase in incidence of Achromobacter xylosoxidans infections caused by
sporadic acquisition from the environment. J Cyst Fibros Dec 2011;10(6):
466–9.
[24] WangX, Dockery DW,Wypij D, FayME, Ferris Jr BG. Pulmonary function
between 6 and 18 years of age. Pediatr Pulmonol Feb 1993;15(2):75–88.
[25] Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values
from a sample of the general U.S. population. Am J Respir Crit Care Med
Jan 1999;159(1):179–87.
[26] Høiby N, Flensborg EW, Beck B, Friis B, Jacobsen SV, Jacobsen L.
Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and
prognostic significance of Pseudomonas aeruginosa precipitins deter-
mined by means of crossed immunoelectrophoresis. Scand J Respir Dis
Apr 1977;58(2):65–79.
[27] Ojeniyi B, Høiby N, Rosdahl VT. Genome fingerprinting as a typing
method used on polyagglutinable Pseudomonas aeruginosa isolates from
cystic fibrosis patients. APMIS Jun 1991;99(6):492–8.
[28] Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Høiby N. Spread of
colistin resistant non-mucoid Pseudomonas aeruginosa among chronically
infected Danish cystic fibrosis patients. J Cyst Fibros Sep 2008;7(5):391–7.
[29] Magni A, Giordano A, Mancini C, Pecoraro C, Varesi P, Quattrucci S,
et al. Emerging cystic fibrosis pathogens: incidence and antimicrobial
resistance. New Microbiol 2007 Jan;30(1):59–62.
[30] Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, et al.
Identification and antimicrobial susceptibility of Alcaligenes
xylosoxidans isolated from patients with cystic fibrosis. J Clin
Microbiol Nov 2001;39(11):3942–5.
[31] Wainwright CE, France MW, O'Rourke P, Anuj S, Kidd TJ, Nissen MD,
et al. Cough-generated aerosols of Pseudomonas aeruginosa and other
bacteria from cystic fibrosis patients. Thorax Jul 1 2009.
[32] Van Daele SG, Franckx H, Verhelst R, Schelstraete P, Haerynck F,
Van Simaey L, et al. Epidemiology of Pseudomonas aeruginosa in a
cystic fibrosis rehabilitation centre. Eur Respir J Mar 2005;25(3):
474–81.
[33] de Baets F, Schelstraete P, van Daele S, Haerynck F, Vaneechoutte M.
Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical
relevance. J Cyst Fibros Jan 2007;6(1):75–8.
615C.R. Hansen et al. / Journal of Cystic Fibrosis 12 (2013) 609–615[34] Lambiase A, Catania MR, Del PM, Rossano F, Terlizzi V, Sepe A, et al.
Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis
patients. Eur J Clin Microbiol Infect Dis Aug 2011;30(8):973–80.
[35] Tan K, Conway SP, Brownlee KG, Etherington C, Peckham DG. Alcaligenes
infection in cystic fibrosis. Pediatr Pulmonol Aug 2002;34(2):101–4.
[36] Dunne Jr WM, Maisch S. Epidemiological investigation of infections due
to Alcaligenes species in children and patients with cystic fibrosis: use of
repetitive-element-sequence polymerase chain reaction. Clin Infect Dis
Apr 1995;20(4):836–41.
[37] Moissenet D, Baculard A, Valcin M, Marchand V, Tournier G,
Garbarg-Chenon A, et al. Colonization by Alcaligenes xylosoxidans in
children with cystic fibrosis: a retrospective clinical study conducted by
means of molecular epidemiological investigation. Clin Infect Dis Feb
1997;24(2):274–5.
[38] Spicuzza L, Sciuto C, Vitaliti G, Di Dio G, Leonardi S, La Rosa M.
Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort
of patients. Eur J Clin Microbiol Infect Dis Feb 2009;28(2):191–5.[39] Hansen CR, Pressler T, Nielsen KG, Jensen PO, et al. Inflammation in
Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst
Fibros Jan 2010;9(1):51–8.
[40] Aanaes K, von Buchwald C, Hjuler T, Skov M, Alanin M, Johansen HK.
Extensive sinus surgery and follow-up can eradicate pathogenic bacterial
sinusitis in patients with cystic fibrosis.J Cyst Fibros 2012;11(Supplement
1):S53 [Ref Type: Abstract].
[41] Roby BB, McNamara J, Finkelstein M, Sidman J. Sinus surgery in cystic
fibrosis patients: comparison of sinus and lower airway cultures. Int J
Pediatr Otorhinolaryngol Sep 2008;72(9):1365–9.
[42] Johansen HK, Aanaes K, Pressler T, Nielsen KG, Fisker J, Skov M, et al.
Colonisation and infection of the paranasal sinuses in cystic fibrosis patients
is accompanied by a reduced PMN response. J Cyst Fibros May 15 2012.
[43] Hansen SK, Rau MH, Johansen HK, Ciofu O, et al. Evolution and
diversification of Pseudomonas aeruginosa in the paranasal sinuses of
cystic fibrosis children have implications for chronic lung infection.
ISME J Jan 2012;6(1):31–45.
